Roughly 16 million American adults are taking GLP-1 medications. They are a major breakthrough for people to shed pounds and ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

A major change to her prescription benefits ... but there are differences.Studies have found that people who used tirzepatide injections such as Zepbound lost more weight and were more likely to reach ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Johnna Byrd began taking Zepbound to help her finish the weight loss journey she started. She never imagined it would help her stop binge drinking.

Studies have found that people who used tirzepatide injections such as Zepbound lost more weight and were more likely to reach specific weight loss targets than those using semaglutide medications ...

Studies have found that people who used tirzepatide injections such as Zepbound lost more weight and were more likely to reach specific weight loss targets than those using semaglutide medications ...

A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s Wegovy, Zepbound maker Eli Lilly said.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...